Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexFemale
Age18-35
SponsorBeni-Suef University
About this trial
The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder.
The main question it aims to answer is:
Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.
Eligibility criteria
Qualifiers
Advanced maternal age (>40 years) or any other risk factor for Poor Ovarian Response (POR).
≤3 oocytes with a conventional stimulation protocol).
An abnormal ovarian reserve test [i.e. antral follicle count (AFC) less than 5-7 follicles or anti-Müllerian hormone (AMH) below 0.5-1.1 ng/ml].
Disqualifiers
Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction.
Any pelvic pathology such as hydrosalpinx, uterine anomaly.
Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia
Trial design
Treatments tested in this trial
- Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.
- DHEA plus folic acid 400mcg per day
- control group
Treatment groups
165 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov